Phase I dose escalation study of recombinant interleukin-21 (rIL-21; BMS-982470) in combination with nivolumab (anti-PD-1; BMS-936558; ONO-4538) in patients (pts) with advanced or metastatic solid tumors.
Laura Quan Man Chow
Research Funding - Bristol-Myers Squibb
Michael S. Gordon
Research Funding - Bristol-Myers Squibb
Theodore F. Logan
Consultant or Advisory Role - Bristol-Myers Squibb
Honoraria - Bristol-Myers Squibb
Research Funding - Bristol-Myers Squibb
Scott J. Antonia
No relevant relationships to disclose
Shailender Bhatia
Research Funding - Bristol-Myers Squibb
John A. Thompson
Consultant or Advisory Role - Bristol-Myers Squibb
Research Funding - Bristol-Myers Squibb
Julie R. Brahmer
Consultant or Advisory Role - Bristol-Myers Squibb (U)
Research Funding - Bristol-Myers Squibb
Gretchen Solberg
Employment or Leadership Position - Bristol-Myers Squibb
Rachel Bittner
Employment or Leadership Position - Bristol-Myers Squibb
David Fontana
Employment or Leadership Position - Bristol-Myers Squibb
Stock Ownership - Bristol-Myers Squibb
Joseph Grosso
Employment or Leadership Position - Bristol-Myers Squibb
Stock Ownership - Bristol-Myers Squibb
Lewis J. Cohen
Employment or Leadership Position - Bristol-Myers Squibb
Stock Ownership - Bristol-Myers Squibb
Christoph Matthias Ahlers
Employment or Leadership Position - Bristol-Myers Squibb
Jon M. Wigginton
Employment or Leadership Position - Bristol-Myers Squibb
Stock Ownership - Bristol-Myers Squibb
Charles G. Drake
Consultant or Advisory Role - Bristol-Myers Squibb